Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
Novel, Noninvasive Skin Cancer Detection Method Shows Promise

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
Flow Cytometry Can Reliably Identify CTC in Melanoma

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Sara L. Douglas, PhD, RN, Frances Payne Bolton School of Nursing, Case Western Reserve University
December 3rd 2020

Dr Sara Douglas: Support Is Often Hard to Come By for Distance Caregivers

Distance caregivers of patients with cancer often find it difficult to enlist adequate support, noted Sara L. Douglas, PhD, RN, associate dean for research at the Frances Payne Bolton School of Nursing at Case Western Reserve University.
Randall Oyer, MD, president of the Association of Community Cancer Centers
November 24th 2020

Dr Randall Oyer on ACCC and ASCO's Work to Reduce Clinical Trial Disparities

Rose McNulty
Randall Oyer, MD, president of the Association of Community Cancer Centers, discusses the ACCC and American Society of Clinical Oncology's initiative to make clinical trials more inclusive.
Using Data to Drive Practice
November 20th 2020

How US Oncology Network Practices Find Success in the OCM

Rose McNulty
The Network enrolled its 100,000th patient in the Oncology Care Model (OCM) recently, and its practices are finding success in the complicated model.
Dr Karen Winkfield
November 17th 2020

Dr Karen Winkfield Discusses Importance of Workforce Diversity in Oncology

Representation of minority populations in the oncology workforce is important to educate physicians on the meaning of being culturally appropriate, and to provide culturally appropriate care.
Doctor Looking at Scan
November 12th 2020

Medicaid Expansion Associated With More Early-Stage Cancer Diagnoses

Rose McNulty
Data in a new analysis showed that Medicaid expansion under the Affordable Care Act had positive effects on rates of early-stage cancer diagnosis, and the results were immediate.
David Jackman, MD, Dana-Farber Cancer Institute
November 10th 2020

Dr David Jackman on Clinical Pathway Buy-in, Update Process

Efficiency, collaboration, and efficacy are key drivers in creating clinical pathway buy-in, with updates also vital to incorporate the latest trends and insights in cancer care.
Medicaid Expansion May Lower Mortality in Cancer Patients
November 5th 2020

Medicaid Expansion May Lower Mortality in Cancer Patients

Rose McNulty
Breast, lung, and colorectal cancer patients in Medicaid expansion states saw lower mortality rates compared with patients in nonexpansion states, a new study found.
How Federal Policy Decisions Are Influencing Cancer Care
November 2nd 2020

How Federal Policy Decisions Are Influencing Cancer Care

Laura Joszt, MA
As novel therapies drive up the cost of cancer care, federal policy decisions are being made that influence oncologists' ability to deliver cancer care, said Debra Patt, MD, PhD, MBA, MPH, of Texas Oncology.
Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM
November 1st 2020

Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM

Through the Oncology Care Model's impact on preventing unnecessary utilization, particularly for in-patient care, resources derived from its use has enhanced care coordination and led to the formation of novel infrastructure and clinical pathways.
Community Oncology Alliance
October 28th 2020

A Closer Look at 3 Oncology Payment Reform Projects

Mary Caffrey
Evolution and collaboration are the fundamentals of bringing oncology payment reform plans to fruition, say 3 professionals on the front lines.
Cancer Does Not Stop for COVID-19, But Reform Becomes a Challenge
October 28th 2020

Cancer Does Not Stop for COVID-19, but Reform Becomes a Challenge

Rose McNulty
During a session on day 1 of the Community Oncology Alliance (COA) Virtual Payer Exchange Summit on Oncology Payment Reform, a panel of experts discussed the ways COVID-19 continues to impact cancer care and payment reform.
Dr. Andre Goy
October 25th 2020

Dr Andre Goy Discusses Potential Benefits of Earlier Use of CAR T Therapies

Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment.
Avalere Webinar on Oncology Care and Payment Reform
October 22nd 2020

Experts Discuss Oncology Care and Payment Reform in Avalere Webinar

Rose McNulty
Experts in cancer care and payment discussed the future of oncology care in a panel discussion hosted by Avalere Health on October 21, 2020.
Dr David Jackman on Dana Farber's Clinical Pathway Development Process
October 21st 2020

Dr David Jackman on Dana Farber's Clinical Pathway Development Process

At Dana Farber Cancer Institute, essential steps to developing clinical pathways include engaging physicians to buy-in, finding the optimal platform to store data, and displaying resulting content in a supportive and efficient way.
Lymphoma cell
October 16th 2020

Hodgkin Lymphoma Patients Face Noncancer Death Risk Despite Modern Therapies

Rose McNulty
A study and accompanying editorial from the Journal of Clinical Oncology found that Hodgkin lymphoma survivors still face a higher risk of non-cancer death than the general population.
Sara L. Douglas, PhD, RN, Case Western Reserve University
October 11th 2020

Dr Sara Douglas: Distance Caregivers of Patients With Cancer Have Distinct Needs

Distance caregivers have unique needs, explained Sara L. Douglas, PhD, RN, the Gertrude Perkins Oliva Professor in Oncology Nursing, associate dean for research, the Frances Payne Bolton School of Nursing, Case Western Reserve University.
Ibrance
October 10th 2020

Phase 2 Trial to Study Palbociclib in Early Stage Breast Cancer Based on ctDNA Monitoring

Rose McNulty
Natera’s Signatera ctDNA test will determine study eligibility and treatment effectiveness in HR-positive, HER2-negative breast cancer patients.
Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology
October 4th 2020

Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations.
Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates
September 30th 2020

Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates

Gianna Melillo
Throughout the United States, counties experiencing persistent poverty have disproportionately higher rates of cancer mortality, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.
Maura Abbott, PhD, AOCNP, CPNP, RN, Columbia University School of Nursing
September 29th 2020

Dr Maura Abbott Explains How Vaccine Form Determines Patient Contraindications

Form will determine in which patient populations, and why, a vaccine is not indicated for administration, said Maura Abbott, PhD, AOCNP, CPNP, RN, assistant professor of nursing at the Columbia University School of Nursing.
Addressing Cancer Disparities Requires Asking Questions and Putting Aside Assumptions
September 28th 2020

Addressing Cancer Disparities Requires Asking Questions and Putting Aside Assumptions

Laura Joszt, MA
Speakers at Patient-Centered Oncology Care® highlighted injustices in the US health care system, the risk of financial toxicity, and how providers can do a better job to ensure their patients achieve health equity, during a panel discussion.
Dr Kashyap Patel Discusses COVID-19 Implications for PCOC® 2020
September 23rd 2020

Dr Kashyap Patel Discusses COVID-19 Implications for PCOC® 2020

The uncertainties precipitated by the coronavirus disease 2019 (COVID-19) pandemic around cancer care delivery are a challenging topic to be further addressed at this year’s Patient-Centered Oncology Care® 2020 virtual meeting.
How Oncology Practices Are Identifying, Addressing Health Needs Amid Pandemic
September 23rd 2020

How Oncology Practices Are Identifying, Addressing Health Needs Amid Pandemic

Through risk stratification and identifying social determinants of health, oncology practices are monitoring the direct and indirect effects of the pandemic, noted Jenifer Leaf Jaeger, MD, MPH, senior medical director of HealthEC.
Dr Joseph Alvarnas on Opportunities Presented by Virtual Format of PCOC® 2020
September 22nd 2020

Dr Joseph Alvarnas on Opportunities Presented by Virtual Format of PCOC® 2020

Through this year's virtual format for Patient-Centered Oncology Care® 2020, participants will be able to attend sessions, ask questions, and gain insight in an immediate, efficient way.
More Coffee, Longer Survival? Study Highlights Benefit in Metastatic Colon Cancer
September 19th 2020

More Coffee, Longer Survival? Study Highlights Benefit in Metastatic Colon Cancer

Allison Inserro
Patients with advanced colon cancer who drank 4 or more cups of coffee a day had 36% improved survival odds.
AACR Report Highlights Disparities in Cancer and the Need for Health Equity
September 18th 2020

AACR Report Highlights Disparities in Cancer and the Need for Health Equity

Laura Joszt, MA
Although innovations in cancer treatment have driven down overall cancer death rates and increased the number of survivors living with cancer, that progress has not benefitted everyone with cancer equally.
PCOC
September 9th 2020

Equity in Care Delivery Still at Top of PCOC 2020 Agenda, Amid “Undue Burden”

Mary Caffrey
Drs Joseph Alvarnas and Kashyap Patel, co-chairs of Patient-Centered Oncology Care® 2020, discuss what attendees can look forward to at the September 25 meeting.
IQVIA
September 7th 2020

Combatting COVID-19 With Real-World Evidence

Jennifer B. Christian, PharmD, MPH, PhD Matthew W. Reynolds, PhD
A vaccine isn’t the panacea many assume it will be. Even when it becomes available, the virus won’t go away. Real world evidence will be needed to guide decision making.
Picture of liver
September 5th 2020

Uptake of Palliative Care in Liver Cancer Needs Improvement, Report Says

Allison Inserro
Hepatocellular carcinoma is rising, and so is the need for increased awareness and use of palliative care, say the authors of a recent review.
Tafasitamab Plus Lenalidomide Added to NCCN Guidelines
August 28th 2020

Tafasitamab Plus Lenalidomide Added to NCCN Guidelines

AJMC Staff
NCCN added tafasitamab plus lenalidomide to their oncology practice guidelines for patients with relapsed or refractory DLBCL not otherwise specified.
<1
...
161718192021222324
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo